Document is current

Article History

Received: 22 July 2025

Accepted: 20 August 2025

First Online: 8 September 2025

Declarations

:

: All authors have completed and submitted the ICMJE disclosures form. Paul Bastelica has no conflicts of interest to declare. Antoine Labbé is a consultant for Alcon, Abbvie, Bausch & Lomb, Elios, Horus Pharma, Glaukos, Théa, and Santen. Marwan Sahyoun declares working as a Medical Advisor at Horus Pharma at the time of publication. Christophe Baudouin is a consultant for Alcon, Glaukos, Horus Pharma, Oculis, Santen, and Théa. Cédric Lamirel is a consultant for Biogen, Gensight, and Horus Pharma and received travel grants from Horus Pharma and Théa, outside the scope of this work. Muriel Poli is a consultant for Bausch & Lomb, Horus Pharma, and Théa. Jean Paul Renard is a consultant for Bausch & Lomb, Horus Pharma, Santen, and Théa. Antoine Rousseau is a consultant for Abbvie, Glaukos, Horus Pharma, and Théa and received speaker honoraria and/or travel grants from Abbvie, Alnylam pharmaceuticals, Bausch & Lomb, Santen, and Théa, outside the scope of this work. Cédric Schweitzer is a consultant for Alcon, Bausch & Lomb, Glaukos, Horus Pharma, Nicox, Santen, and Théa. Florent Aptel is a consultant for Alcon, Bausch & Lomb, Densmore, Elios, Eyetechcare, Glaukos, Horus Pharma, and Théa.

: The study adhered to the principles of the Declaration of Helsinki and received approval from the Rothschild Foundation Hospital review board (IRB 00012801) under study number CE_20240528_2_CLL.